Epithalon vs Pinealon: Two Khavinson Peptide Bioregulators Compared

Published October 2026 · Patriot Labs Research Team · ~16 min read

The short answer

Epithalon is a four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), modeled on a pineal-gland extract and studied mainly in telomerase and aging research; Pinealon is a three-amino-acid peptide, Glu-Asp-Arg (EDR), derived from a brain-cortex preparation and studied mainly in neuroprotection and gene-expression research. They share a research framework — both are “short peptide bioregulators” from the same Russian group — but they are distinct molecules with different sequences, tissue associations and bodies of literature.

The quickest way to keep them apart is by the organ and the headline idea attached to each. Epithalon traces to the pineal gland and is best known in research for a 2003 report that it switched on telomerase in cultured human cells.^[2] Pinealon — despite a name that sounds pineal — traces to a cortex-derived preparation and is best known in research as a neuroprotective tripeptide studied in models of brain stress and Alzheimer’s disease.^[5]

Everything else in this guide follows from those two facts: a pineal tetrapeptide with a telomerase association versus a cortical tripeptide with a neuronal-gene-expression association. Both are laboratory research compounds, neither is an approved drug, and most of the published evidence for each comes from one research program — a limitation worth carrying through the whole comparison. The single-compound detail lives in What Is Epithalon? and What Is Pinealon?

At a glance: the core differences

The two peptides differ on sequence, length, tissue origin, the mechanism each is studied around, and the research field in which each mostly appears. The table below summarizes the contrasts developed in the rest of the guide.

What Epithalon is

Epithalon is a synthetic tetrapeptide with the sequence Ala-Glu-Asp-Gly, almost always abbreviated AEDG, and it is also spelled Epitalon in much of the literature. It was developed within the Russian peptide-bioregulator program led by Vladimir Khavinson at the St. Petersburg Institute of Bioregulation and Gerontology, as a short synthetic peptide modeled on the amino-acid composition of Epithalamin, a peptide preparation obtained from the pineal gland.^[1] A 2025 review in the International Journal of Molecular Sciences describes it as a “highly bioactive pineal tetrapeptide” and frames its interest around geroprotection.^[1]

The single most-cited thing about Epithalon is its reported effect on telomerase. In 2003, Khavinson, Bondarev and Butyugov reported in Bulletin of Experimental Biology and Medicine that the peptide “induces telomerase activity and telomere elongation in human somatic cells” in culture.^[2] That finding — telomerase activation in cultured fibroblasts — is the reason Epithalon appears constantly in longevity and anti-aging discussions, and it is covered in depth in What Is Epithalon? and in the context of other longevity-adjacent compounds in Best Peptides for Anti-Aging & Longevity Research.

Beyond the telomerase work, Epithalon has been studied by the same group in rodent aging experiments — for example a 2003 study reporting effects on biomarkers of aging and spontaneous tumor incidence in a strain of mice^[3] — and in cell models of gene expression and neurogenesis, where the AEDG peptide is described as stimulating gene expression and protein synthesis through a proposed epigenetic route.^[4] Those studies are the substance behind the “geroprotector” label; what they do and do not establish is taken up in the evidence section below.

What Pinealon is

Pinealon is a synthetic tripeptide with the sequence Glu-Asp-Arg, abbreviated EDR. Despite the pineal-sounding name, its sequence was identified from a different source: the 2021 Molecules paper describing it states plainly that EDR (Glu-Asp-Arg, Pinealon) is “a tripeptide isolated from the polypeptide neuroprotective drug Cortexin,” a preparation made from brain cortex.^[5] So while Epithalon is a pineal peptide, Pinealon is, by origin, a cortical one — a distinction the names actively obscure.

In the research literature Pinealon is characterized as a neuroprotective peptide. The same 2021 paper examines it as a possible regulator of gene expression and protein synthesis relevant to the pathogenesis of Alzheimer’s disease, and a 2021 study in Pharmaceuticals places EDR among tripeptide “epigenetic regulators” studied in a mouse model of Alzheimer’s disease.^[5][6] That neuronal framing is why Pinealon sits alongside cognition- and sleep-oriented compounds in Best Peptides for Cognition rather than in the longevity group, and the single-compound background is in What Is Pinealon?

The proposed mechanism for Pinealon is explicitly a gene-expression one. According to the 2021 paper, “the EDR peptide is assumed to enter cells and bind to histone proteins and/or ribonucleic acids,” and in doing so “can change the activity of the MAPK/ERK signaling pathway.”^[5] In other words, Pinealon is studied not as a structural or enzymatic agent but as a very small molecule proposed to reach the cell nucleus and influence which genes are expressed in neurons — the same general idea applied, in Epithalon’s case, to telomerase and aging.

Origin: two glands, two source extracts

The cleanest distinction between the two is where their sequences came from. Both are examples of the Khavinson group’s method of taking a complex tissue-derived peptide preparation and identifying a short “active” sequence within it — but the two preparations are from different organs.

Epithalon’s sequence was derived from Epithalamin, a peptide complex extracted from the pineal gland, the small endocrine structure best known for producing melatonin.^[1] That pineal lineage is the origin of Epithalon’s long association with circadian and aging research: the pineal gland is a recurring character in theories of biological aging, and a short peptide drawn from a pineal extract inherited that framing. Pinealon’s EDR sequence, by contrast, was identified in Cortexin, a polypeptide preparation derived from brain cortex and used clinically in some countries as a neuroprotective agent.^[5] Its research identity is therefore neuronal from the start.

Two consequences follow. First, the naming is misleading: “Pinealon” evokes the pineal gland, but the compound’s documented source preparation is cortical, and its studied activity is in neurons. Second, both peptides are “natural” in the limited sense that their sequences were found in tissue extracts, while the material sold for research is made by chemical synthesis — the same natural-sequence-but-manufactured situation discussed in Recombinant vs Synthetic Peptides and What Are Peptides? Neither uses non-natural building blocks, which is part of why both are chemically simple to describe even though their biology is not.

Mechanism: a telomerase angle vs a gene-expression angle

Both peptides are studied under the same broad hypothesis — that a very short peptide can reach the cell nucleus and change gene expression — but the headline mechanism attached to each is different. For Epithalon the emphasis is telomerase; for Pinealon it is neuronal signaling and gene expression. None of what follows is a claim about any effect in a person; each description summarizes how the compound is understood to act in laboratory research.

How Epithalon is understood to work

Epithalon’s most distinctive proposed mechanism is the induction of telomerase, the enzyme that extends the protective telomere caps at the ends of chromosomes. The 2003 cell-culture study reported both telomerase activity and telomere elongation in human somatic cells exposed to the peptide, and a related report from the group described cells overcoming their usual division limit.^[2] A 2025 review summarizes the resulting view that telomere-length effects “can explain most of the geroprotective effects of this compound,” while noting that “it remains uncertain whether these are the sole mechanisms of action.”^[1] Alongside the telomerase story, Epithalon is also studied as a gene-expression regulator: the AEDG peptide is reported to stimulate gene expression and protein synthesis during neurogenesis through a proposed epigenetic mechanism.^[4]

How Pinealon is understood to work

Pinealon’s mechanism is framed entirely around gene expression rather than telomerase. The 2021 Molecules paper proposes that the EDR peptide enters the cytoplasm and nucleus, binds histone proteins and/or RNA, and modulates the MAPK/ERK signaling pathway, altering the expression of genes implicated in Alzheimer’s pathology.^[5] A companion 2022 review in the International Journal of Molecular Sciences generalizes the idea, describing “ultrashort peptides (2–4 amino acid residues)” as “signaling molecules involved in the homeostasis regulation at various organismal levels” and the EDR peptide’s activity as “associated with its ability to penetrate into the cytoplasm and the cell nucleus and regulate gene expression.”^[8]

So the two operate within one theory but point it at different targets. Epithalon’s literature foregrounds an enzyme, telomerase, and the aging of dividing cells; Pinealon’s foregrounds signaling and gene expression in neurons. That difference in emphasis — not a difference in the underlying “short peptide reaches the nucleus” hypothesis — is what separates their research fields.

Structure and chemistry

Chemically the two peptides are close cousins: both are very short chains of ordinary amino acids with free termini and no non-natural residues. The differences are in one residue of length and in the specific amino acids, which is enough to give each a distinct mass, charge and interaction profile.

One chemically meaningful contrast is charge. Epithalon carries two acidic side chains (glutamate and aspartate) and no basic residue, so it is net negatively charged at neutral pH. Pinealon carries the same acidic pair at its first two positions but ends in arginine, a strongly basic residue, giving it a mixed charge profile. In the Khavinson group’s own modeling, the arginine in EDR and similar sequences is treated as important for how the peptide is proposed to associate with DNA and be carried into cells — work on “transport of biologically active ultrashort peptides” examines how such peptides may use amino-acid transporters to enter cells.^[10] Because both peptides are built only from standard amino acids with free termini, neither carries the half-life-extending modifications — D-amino acids, terminal amides, lipidation — discussed in Peptide Half-Life Extension; both are expected to be short-lived in a biological setting and are handled as ordinary peptide substrates. How peptides of this kind are assembled and purified is covered in How Peptides Are Made.

Where each one appears in research

Because their headline mechanisms differ, the two peptides appear in largely separate research literatures: Epithalon in aging, telomere and longevity work; Pinealon in neuroprotection and neurodegeneration models. Knowing which field a paper is in is usually the fastest way to tell which peptide it concerns.

Epithalon: aging, telomeres and longevity

Epithalon’s literature is dominated by geroprotection. The founding telomerase study^[2] is paired with rodent-aging work from the same group, such as the 2003 report on biomarkers of aging, life span and spontaneous tumor incidence in a mouse strain,^[3] and with cell studies of gene expression during neurogenesis.^[4] More recent secondary literature keeps it in that frame: the 2025 IJMS overview treats it as a geroprotective pineal tetrapeptide,^[1] and a 2026 review in Frontiers in Aging on “therapeutic peptides in gerontology” situates the AEDG peptide among compounds discussed for healthy-aging research.^[11] The telomere connection also links Epithalon to the broader, and cautionary, telomerase-and-cancer literature, because the same enzyme it is reported to activate is abnormally reactivated in most human cancers^[12] — a point returned to in the limits section.

Pinealon: neuroprotection and neurodegeneration models

Pinealon’s literature sits in neuroscience. The EDR peptide has been studied as a possible regulator of gene expression in Alzheimer’s-disease models,^[5] as one of a set of neuroprotective tripeptide “epigenetic regulators” in a mouse model of the disease,^[6] and, more broadly, in work on how short peptides may protect neurons from age-related and stress-related change — a 2024 IJMS study reports that short peptides protect fibroblast-derived induced neurons from age-related changes.^[9] The recurring theme is the aging or stressed neuron, not the dividing fibroblast, which is the mirror image of where Epithalon’s telomere work sits. Both compounds also appear together in the group’s systematic review of peptide regulation of gene expression, which is the umbrella under which the whole program is organized.^[7]

The shared idea: short peptide bioregulators

Epithalon and Pinealon are most meaningfully understood as two members of a single research program: the Khavinson group’s “short peptide bioregulators,” also called ultrashort peptides. Seeing them as siblings explains both why they are constantly compared and why neither should be read as evidence for the other.

The program’s central claim, set out in its 2021 systematic review of peptide regulation of gene expression, is that very short peptides of two to four amino acids can act as signaling molecules that reach the cell nucleus and influence which genes are expressed.^[7] The 2022 review states the idea in general terms — ultrashort peptides as “signaling molecules involved in the homeostasis regulation at various organismal levels” whose activity is tied to penetrating the cytoplasm and nucleus and regulating gene expression.^[8] Within that framework, each specific peptide is matched to a tissue and a gene set: AEDG (Epithalon) to the pineal/telomerase/aging axis, EDR (Pinealon) to the cortical/neuronal axis, with other sequences in the family mapped to other organs. Work on how these peptides are transported into cells — via peptide and amino-acid transporters — is part of the same effort to give the hypothesis a concrete molecular basis.^[10]

Two things follow for anyone comparing them. First, the shared framework is exactly why they appear together: they are variations on one method, not competitors for one job. Second, that shared origin is also the main evidentiary caveat. Much of the supporting literature comes from the same group and the same institute; independent replication by unaffiliated laboratories is comparatively limited, and a 2026 preprint attempting to screen longevity interventions, including peptides of this kind, in mice is explicitly not peer-reviewed. A hypothesis that is internally consistent across a program is not the same as one confirmed from the outside, and that distinction matters more here than the differences between the two peptides.

Regulatory and evidence status

On regulatory status the two peptides are the same: neither Epithalon nor Pinealon is an approved drug anywhere that matters for a US buyer, and both are sold strictly as research compounds. What differs slightly is the shape of the evidence behind each — but both share the same fundamental limitation.

Neither peptide has US Food and Drug Administration approval, and neither has a large, independently replicated body of randomized controlled trials in humans. The pineal and cortical source preparations they derive from — Epithalamin and Cortexin — have a history of clinical use in Russia and some neighboring countries, but that regional regulatory history applies to those specific preparations, not to the isolated synthetic peptides sold for research, and it does not translate into FDA approval or into Western clinical acceptance. The human data that exist for Epithalon in particular come largely from the originating group and from small studies, which is a recognized constraint when weighing the claims.

The point that cuts across both, and across the research market generally, is that a research compound is not a medicine. Material labeled Epithalon or Pinealon and sold for laboratory use has not been manufactured under an approved drug’s regulated, inspected quality system, has not been through that kind of release testing, and is not sold for use in people. The distinction between research-grade and pharmaceutical-grade material is set out in Peptide vs Drug vs Biologic, and what independent testing can and cannot show is covered in Understanding Peptide COA Testing. For this comparison, treat both peptides as laboratory compounds of scientific interest, not as products with established human use.

Are they studied together?

Epithalon and Pinealon are frequently listed together because they belong to the same peptide family, but in the primary literature they are treated as distinct tools aimed at different tissues, not as a combination. This section describes how the two are positioned in research; it is not a protocol and does not describe combining anything for use.

The conceptual reason they are paired is the shared bioregulator hypothesis: both are short peptides proposed to influence gene expression, and they often appear in the same review articles mapping the family onto different organs.^[7][8] But their studied targets barely overlap. Epithalon’s research centers on telomerase and dividing cells in the context of aging; Pinealon’s centers on gene expression and signaling in neurons. One is studied as a geroprotector, the other as a neuroprotector, and the literatures rarely intersect except at the level of the general theory.

What the published work does not provide is any established human regimen for either peptide, let alone the two in combination. Both remain, for the purposes of a research catalogue, laboratory compounds without approved human use. Anyone comparing them for study design should treat them as two separate sequences with separate evidence bases, and should go to the primary sources rather than rely on the convenience of a shared “Russian peptide bioregulator” label. For the single-compound detail, see What Is Epithalon? and What Is Pinealon?

Sourcing, testing and quality

For research material, the questions that matter are identical for both peptides and have nothing to do with which mechanism is more interesting: is the vial what the label says, and is that claim backed by lot-specific documentation? Identity and purity are established the same way for a three-residue peptide as for a four-residue one — by analytical testing, not by branding or by the compound’s reputation.

Two techniques carry most of the weight. High-performance liquid chromatography (HPLC) measures purity: it separates the target peptide from truncated chains, deletion sequences and other process-related impurities and reports the target as a percentage of the whole. Mass spectrometry establishes identity: it measures the molecular mass and confirms it matches the intended sequence — a useful check here because Epithalon (≈390 g/mol) and Pinealon (≈418 g/mol) have distinct, specific masses, and because very short peptides are easy to misidentify by name alone. A certificate of analysis (COA) that names the lot, the methods and the testing laboratory ties those results to the physical material in hand; Understanding Peptide COA Testing explains how to read one, and Peptide Purity Grades Explained covers what a purity percentage does and does not mean.

For reference: Patriot Labs is a first-responder-owned, US-based company, and every batch it sells is tested by an independent US laboratory by HPLC and mass spectrometry, with the certificate of analysis published on the product page. Those are the same documents this section recommends asking any vendor for, whichever compound is in the vial. The product pages for these two peptides are Epithalon and Pinealon.

What this comparison does not establish

This guide compares two research compounds as objects of study. It does not establish anything about their use in people or animals, and several of its points come with limits worth stating plainly.

• Nothing here describes use in a person or animal. Mechanisms are described as they are studied in the laboratory; none of it is guidance for use, and no dose, route or regimen is given for either peptide.
• Much of the evidence comes from one program. A large share of the published work on both peptides originates from the Khavinson group and the St. Petersburg institute. Independent replication by unaffiliated laboratories is comparatively limited, and some recent screening work remains in preprint form and is not peer-reviewed.
• Mechanisms are proposed models, not settled fact. The telomerase account of Epithalon and the nucleus-penetration/gene-expression account of Pinealon are the leading published explanations, but the idea that peptides this short reach the nucleus and direct gene expression is still debated and under investigation.
• Telomerase activation is a double-edged property. The same telomerase enzyme that Epithalon is reported to activate in culture is abnormally reactivated in most human cancers,^[12] so a telomerase-activating property is not straightforwardly beneficial and is a reason for caution, not a selling point.
• Neither is an approved drug. No claim is made that either peptide is safe or effective for any use in humans; both are laboratory research compounds only.
• “Better” is not a meaningful question here. The two peptides are studied for different things in different tissues; which is more relevant depends entirely on the research question, not on any ranking.

Frequently asked questions

What is the difference between Epithalon and Pinealon?

Epithalon and Pinealon are both short synthetic peptides developed within the same Russian peptide-bioregulator research program, but they are different molecules. Epithalon (also spelled Epitalon) is a four-amino-acid peptide, Ala-Glu-Asp-Gly (AEDG), modeled on a pineal-gland extract and studied mainly in telomerase, longevity and aging research. Pinealon is a three-amino-acid peptide, Glu-Asp-Arg (EDR), derived from a brain-cortex preparation and studied mainly in neuroprotection and gene-expression research. One is a tetrapeptide with a pineal and telomerase association; the other is a tripeptide with a cortical and neuronal association.

Are Epithalon and Pinealon the same thing?

No. They are two distinct peptides with different sequences, lengths and research histories. Epithalon is the tetrapeptide AEDG (Ala-Glu-Asp-Gly); Pinealon is the tripeptide EDR (Glu-Asp-Arg). They share a conceptual framework as short peptide bioregulators proposed to influence gene expression, and they come from the same St. Petersburg research group, which is why they are often mentioned together, but they are not interchangeable and do not have the same sequence.

Is Epithalon a telomerase activator?

In laboratory research, Epithalon (AEDG) is studied as a telomerase activator. A 2003 study by Khavinson and colleagues reported that the peptide induced telomerase activity and telomere elongation in cultured human somatic cells. That is a finding in cell culture from one research group; it is not an established effect in people, and telomerase activation is itself a double-edged property because the same enzyme is active in most cancers. Pinealon is not characterized as a telomerase activator; its studied mechanism centers on gene expression in neurons.

What is Pinealon studied for in research?

Pinealon (EDR) is studied mostly in neuroprotection, oxidative-stress and gene-expression research. Published laboratory work describes the tripeptide penetrating into the cytoplasm and cell nucleus and modulating the expression of genes in neurons, including in models related to Alzheimer’s disease and hypoxic or oxidative stress. As with Epithalon, this is preclinical, largely in-vitro and animal research, and no outcome in humans is established.

Are Epithalon and Pinealon FDA approved?

No. Neither Epithalon nor Pinealon is approved by the US Food and Drug Administration, and neither has a large, independently replicated body of randomized controlled human trials. Both are sold only as research compounds for laboratory use. Much of the published literature on each comes from a single Russian research program, which is a limitation when weighing the evidence.

Are Epithalon and Pinealon natural peptides?

Both sequences were identified from natural tissue extracts — Epithalon from a pineal-gland preparation and Pinealon’s EDR sequence from a cortex-derived preparation — so their sequences have a natural origin. The material sold for research, however, is made by chemical synthesis. Both also contain only standard amino acids, unlike many engineered peptides that use non-natural building blocks.

References

1. Araj, S. K., Brzezik, J., Mądra-Gackowska, K., & Szeleszczuk, Ł. (2025). Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences, 26(6), 2691. doi:10.3390/ijms26062691
2. Khavinson, V. K., Bondarev, I. E., & Butyugov, A. A. (2003). Epithalon Peptide Induces Telomerase Activity and Telomere Elongation in Human Somatic Cells. Bulletin of Experimental Biology and Medicine, 135(6), 590–592. doi:10.1023/A:1025493705728
3. Anisimov, V. N., Khavinson, V. Kh., Popovich, I. G., et al. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology, 4(4), 193–202. doi:10.1023/A:1025114230714
4. Khavinson, V., Diomede, F., Mironova, E., Linkova, N., Trofimova, S., Trubiani, O., Caputi, S., & Sinjari, B. (2020). AEDG Peptide (Epitalon) Stimulates Gene Expression and Protein Synthesis during Neurogenesis: Possible Epigenetic Mechanism. Molecules, 25(3), 609. doi:10.3390/molecules25030609
5. Khavinson, V., Linkova, N., Kozhevnikova, E., & Trofimova, S. (2021). EDR Peptide: Possible Mechanism of Gene Expression and Protein Synthesis Regulation Involved in the Pathogenesis of Alzheimer’s Disease. Molecules, 26(1), 159. doi:10.3390/molecules26010159
6. Khavinson, V., Ilina, A., Kraskovskaya, N., Linkova, N., Kolchina, N., Mironova, E., Erofeev, A., & Petukhov, M. (2021). Neuroprotective Effects of Tripeptides—Epigenetic Regulators in Mouse Model of Alzheimer’s Disease. Pharmaceuticals, 14(6), 515. doi:10.3390/ph14060515
7. Khavinson, V. K., Popovich, I. G., Linkova, N. S., Mironova, E. S., & Ilina, A. R. (2021). Peptide Regulation of Gene Expression: A Systematic Review. Molecules, 26(22), 7053. doi:10.3390/molecules26227053
8. Ilina, A., Khavinson, V., Linkova, N., & Petukhov, M. (2022). Neuroepigenetic Mechanisms of Action of Ultrashort Peptides in Alzheimer’s Disease. International Journal of Molecular Sciences, 23(8), 4259. doi:10.3390/ijms23084259
9. Kraskovskaya, N., Linkova, N., Sakhenberg, E., et al. (2024). Short Peptides Protect Fibroblast-Derived Induced Neurons from Age-Related Changes. International Journal of Molecular Sciences, 25(21), 11363. doi:10.3390/ijms252111363
10. Khavinson, V., Linkova, N., Kozhevnikova, E., Dyatlova, A., & Petukhov, M. (2022). Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers. International Journal of Molecular Sciences, 23(14), 7733. doi:10.3390/ijms23147733
11. Bolgova, O., Mavrych, V., & Shypilova, I. (2026). Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. Frontiers in Aging, 7, 1790247. doi:10.3389/fragi.2026.1790247
12. Yuan, X., Larsson, C., & Xu, D. (2019). Mechanisms underlying the activation of TERT transcription and telomerase activity in human cancer: old actors and new players. Oncogene, 38(34), 6172–6183. doi:10.1038/s41388-019-0872-9
13. National Center for Biotechnology Information. PubChem Compound Summary for CID 219042, Epitalon (C₁₄H₂₂N₄O₉). pubchem.ncbi.nlm.nih.gov/compound/219042
14. National Center for Biotechnology Information. PubChem Compound Summary for CID 10273502, Glu-Asp-Arg (Pinealon; C₁₅H₂₆N₆O₈). pubchem.ncbi.nlm.nih.gov/compound/10273502

For more on the compounds and concepts this guide touches, see What Is Epithalon? and What Is Pinealon? for the single-compound explainers, Best Peptides for Anti-Aging & Longevity Research for the field Epithalon sits in, Best Peptides for Cognition for the field Pinealon sits in, and Understanding Peptide COA Testing for how identity and purity are verified.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and compares two compounds in general scientific terms; it is not medical advice, does not describe how to use any product, and makes no claim about outcomes in humans or animals. A research compound that shares a name with a clinical preparation is not that preparation.